Nonscarring inflammatory alopecia associated with the epidermal growth factor receptor inhibitor gefitinib - 09/08/11
Reprint requests: Michael P. Heffernan, MD, Division of Dermatology, Wright State University School of Medicine, One Elizabeth Pl, Suite 200, Dayton, OH 45408-1445.St Louis, Missouri; Albuquerque, New Mexico; and Dayton, Ohio
Abstract |
Gefitinib (ZD1839, Iressa, AstraZeneca, Wilmington, Del) is a novel oral anticancer agent that acts by blocking the function of the epidermal growth factor receptor. Gefitinib and other drugs that block epidermal growth factor receptor function have been associated with a similar and interesting pattern of cutaneous adverse effects, including follicular acneiform eruptions, xerosis, desquamation, seborrheic dermatitis, chronic paronychia, and hair texture changes. These effects appear to reflect the significance of epidermal growth factor receptor signaling in the skin. Here we present a case of a woman who developed an extensive nonscarring inflammatory alopecia after 2 years of gefitinib therapy.
Le texte complet de cet article est disponible en PDF.Plan
| Funding sources: None. Conflicts of interest: None identified. |
Vol 55 - N° 2
P. 349-353 - août 2006 Retour au numéro
Article précédent
- Nodular mastocytosis
- Sarah Kasprowicz, I.-Ja Chan, Daniel J. Wall, Michael D. Tharp
- Atypical pemphigus involving the esophagus with IgG antibodies to desmoglein 3 and IgA antibodies to desmoglein 1
- Shigeki Inui, Masayuki Amagai, Shusaku Tsutsui, Saho Fukuhara-Yoshida, Satoshi Itami, Ichiro Katayama
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?